Health Catalyst (HCAT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Health Catalyst (HCAT) reported Q3 2025 revenue of $76.32 million, matching the prior year's figure and exceeding the Zacks Consensus Estimate of $75.08 million by 1.66%. EPS for the quarter was $0.06, a 20% beat over the $0.05 consensus, despite being down from $0.07 year-over-year. Segment performance showed Technology revenue growing 7% year-over-year to $52.05 million, while Professional Services revenue declined 12.4% to $24.27 million, with both segments' revenues and adjusted gross profits surpassing analyst estimates. HCAT shares have outperformed the broader market, returning 6.8% over the past month.

Analysis

Health Catalyst (HCAT) reported Q3 2025 revenue of $76.32 million, aligning with prior year figures and surpassing the Zacks Consensus Estimate of $75.08 million by 1.66%. Earnings Per Share (EPS) came in at $0.06, a 20% beat against the $0.05 consensus, despite a slight year-over-year decline from $0.07. This indicates effective management of expectations and operational efficiency.

The company's performance was notably driven by its Technology segment, which saw a 7% year-over-year revenue increase to $52.05 million, exceeding the $52 million estimate. Conversely, Professional Services revenue declined 12.4% year-over-year to $24.27 million, though it still surpassed the $23.08 million analyst estimate. Both segments also reported adjusted gross profits above analyst expectations, highlighting strong cost management within each division.

HCAT shares have demonstrated strong recent momentum, returning +6.8% over the past month, significantly outperforming the S&P 500's +0.3% change. Despite this outperformance and the positive earnings surprises, the stock currently holds a Zacks Rank #3 (Hold), suggesting an expectation for near-term performance in line with the broader market rather than continued significant outperformance.

Key Decisions for Investors

• Investors should note HCAT's consistent ability to exceed consensus estimates for both top and bottom lines, indicating strong operational execution.
• The divergent segment performance, with robust Technology revenue growth offsetting Professional Services declines, suggests a strategic shift or evolving business mix that warrants deeper analysis.
• While recent stock outperformance is positive, the Zacks Rank #3 (Hold) implies a balanced near-term outlook, suggesting investors monitor future guidance and competitive landscape closely.